^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China

Published date:
12/31/2020
Excerpt:
This was a single‐arm, open‐label, multicenter clinical trial design evaluating relma‐cel in adult (≥18 years) patients with CD19+ r/r LBCL....Patients who achieved any response had lower baseline levels of serum TNF‐α and responding patients also had lower peak concentrations for TNF‐α and IFN‐γ (p < 0.01; Figure 4C).
DOI:
10.1002/cam4.3686
Trial ID: